{"id":"saxagliptin-plus-metformin-ir","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Urinary tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance (metformin-related)"}]},"_chembl":{"chemblId":"CHEMBL2103745","moleculeType":"Small molecule","molecularWeight":"333.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saxagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing insulin secretion in response to meals and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose output and increases peripheral glucose uptake and utilization. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:34.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT01525225","phase":"PHASE1","title":"Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes Mellitus","enrollment":4},{"nctId":"NCT00885378","phase":"PHASE3","title":"Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT00899470","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00897390","phase":"PHASE1","title":"Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00327015","phase":"PHASE3","title":"A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Diabetes","enrollment":1306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-477118","Onglyza"],"phase":"phase_3","status":"active","brandName":"Saxagliptin plus metformin IR","genericName":"Saxagliptin plus metformin IR","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}